Background--The results of recent studies suggest that dipeptidyl-peptidase-4 inhibitors have antiatherogenic effects. However, whether or not dipeptidyl-peptidase-4 inhibitors could suppress arterial inflammation and intimal hyperplasia after injury remains undetermined. The present study aims to clarify the anti-inflammatory effects of the dipeptidyl-peptidase-4 inhibitor, alogliptin (AGP), on the arteries of atherogenic low-density lipoprotein receptor-deficient (LKO) mice.
D
ipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral antihyperglycemic agents for treating type 2 diabetes mellitus patients. Recent studies suggest that several DPP-4 inhibitors exert antiatherosclerotic effects though suppressing inflammatory reactions of monocytes and smooth-muscle cell (SMC) proliferation in vitro. [1] [2] [3] However, whether or not DPP-4
inhibitors suppress arterial inflammation and intimal hyperplasia after injury remains undetermined.
Alogliptin (2-({6-[(3R)-3-aminopiperidinyl-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)yl} methyl)benzonitrile monobenzoate) (AGP) is a selective DPP-4 inhibitor that has also improves glycemic control. [4] [5] [6] [7] Shah et al indicated that AGP suppresses inflammatory chemokine expression and the migration of bone marrow-derived monocytes in vitro. 1 However, it remains unknown whether AGP has anti-inflammatory effects and reduces neointimal hypertrophy in an artery injury model.
Methods Animals
The study was performed using low-density lipoprotein receptor-deficient (LKO) mice (8 to 10 weeks of age), which are known to have atherogenic properties in a cuff-injury model. 8 LKO mice were fed with standard chow. The
DPP-4 Inhibitor
The DPP-4 inhibitor, alogliptin benzonate (Takeda Pharmaceutical Company, Tokyo; 136 mg) was dissolved in distilled water to a final concentration of 1 mg/mL, stored at 4°C, and warmed to room temperature before use.
Femoral Artery Injury and AGP Administration
Only male mice were studied to exclude gender differences. The mice were anesthetized by intraperitoneal injection of pentobarbital (50 mg/kg), and we dissected the left femoral artery from its surrounding, as demonstrated previously. 9 Vascular injury was inflicted by placing a nonocclusive polyethylene cuff (length 2 mm; internal diameter 0.56 mm; Becton Dickinson, Mountain View, CA) around the femoral artery. We administered AGP (20 mg/kg per day) or normal saline by oral injection once daily to the mice for 14 days.
Blood Pressure Measurement
Systolic blood pressure was measured in nonanesthetized mice at 13 days postinjury by the tail-cuff method (MK-2000; Muromachi Kikai).
Levels of Plasma Lipid, Glucose, and Active Glucagon-Like Peptide-1
Mice were fasted for 12 hours and blood samples were collected from the tail veins of both groups at 14 days postinjury. Levels of plasma total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were measured using high-performance liquid chromatography (Skylight Biotech Inc, Akita, Japan) as described previously. 10 Levels of plasma fasting blood glucose were measured using Free Style Freedom (Nipro Co, Osaka, Japan). Levels of active glucagon-like peptide-1 (GLP-1) were measured in plasma from nonfasted mice using ELISA kits (Shibayagi Co, Gunma, Japan) at 14 days postinjury. Blood samples for measurement of active GLP-1 were immediately collected into tubes containing 1% AGP (10 mmol/L) vol/vol.
Arterial Harvest and Morphometric Analysis
After blood collection, the animals were euthanized by pentobarbital injection and the vascular tree was perfused with 0.9% NaCl followed by 4% paraformaldehyde. After the perfusion procedure, the femoral artery was harvested and fixed with 10% neutral-buffered formalin for 48 hours, embedded in paraffin, and sectioned (each 5-lm thickness).We used equally spaced (200-lm interval) 10 crosssections to qualify a neointimal lesion for each mouse. The samples were stained with elastica van Gieson, and then photographed using an ECLIPS LV100 microscope (Nikon, Tokyo, Japan). The luminal, neointimal, and medial areas were calculated using NIH Image J 1.42 (National Institutes of Health, public domain software).
Immunohistochemistry
Smooth muscle cells were visualized using a-smooth muscle cell actin staining (N1584; DAKO, Tokyo, Japan), cell proliferation was investigated using proliferating cell nuclear antigen staining (N1529; DAKO, Tokyo, Japan), and inflammatory cells were detected by lymphocyte antigen 6 complex staining (N550291; BD Pharmingen in Japan, Tokyo, Japan). The proliferating cell nuclear antigen and the lymphocyte antigen 6 complex indexes were calculated as ratios of stained areas per total intimal area of injured arteries. In addition, anti-tumor necrosis factor-a (TNF-a) staining (ab-6671; Abcam, Cambridge, MA) was used to detect cytokine expressions and the extent of the TNF-a, and monocyte chemoattractant protein 1 (MCP-1) antibody (sc-1785; Santa Cruz Biotechnology) was used for detection of MCP-1 expression and evaluation for positive area per total intimal and medial area of injured arteries. Nuclear translocation of nuclear factor-jB (NF-jB) was detected by phospho-NF-jB p65 (ser276) (pNF-jB) staining (#3037; Cell Signaling Technology). Activation of pNF-jB was evaluated for percentage of positive nuclei in the intima and media or in the adventitia within a 50 lm radius from the external elastic lamina of injured arteries.
Quantitative Real-Time Polymerase Chain Reaction (PCR)
Total RNA from the injured femoral artery was isolated at 3 days postinjury using the TRI reagent (Sigma-Aldrich) (2 vessels for each sample). Complementary DNA was prepared from total RNA (500 ng) using reverse transcriptase according to the manufacturer's instructions (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems). Quantitative mRNA expression was assessed by real-time PCR with Power SYBR Green PCR Master Mix (Applied Biosystems) using primers specific for TNF-a (forward: TCC CAG GTT CTC TTC AAG GGA, reverse: GGT GAG GAG CAC GTA GTC GG), MCP-1 (forward: CCT GGA TCG GAA CCA AAT GA, reverse: CGG GTC AAC TTC ACA TTC AAA G), interleukin (IL)-1b (forward: TGG TGT GTG ACG TTC CCA TT, reverse: CAG CAC GAG GCT TTT TTG TTG), and GAPDH (forward: GTC ATT GAG AGC AAT GCC AG, reverse: GTG TTC CTA CCC CCA ATG TG). Samples were run on the 7500 Fast RealTime PCR system (Applied Biosystems). Data were analyzed by 7500 Software (Applied Biosystems), and relative expression levels of target mRNA of the AGP treatment group was compared with those of the control group. 
Statistical Analysis

Results
LKO mice were treated with normal saline (control) or AGP for 14 days after cuff injury ( Figure 1A ). Blood pressure, fasting blood sugar, and serum cholesterol levels were similar at 2 weeks after cuff injury between the AGP-and saline-treated groups ( Figure 1B ). The nonfasting plasma levels of active GLP-1 were higher in mice treated with AGP than with saline (22.2AE1.9 versus 15.6AE0.9 pg/mL; P<0.05) ( Figure 1C ).
Neointimal Formation After Cuff Injury
We investigated the effect of AGP treatment on arterial inflammation in LKO mice after cuff-induced injury. Figure 2A shows representative cross-sections of femoral arteries harvested from AGP-and saline-treated LKO mice at 14 days postinjury. Quantitative analysis demonstrated that AGP significantly reduced the amount of intimal hyperplasia (1087AE127 versus 1896AE140 lm 2 ; P<0.001) ( Figure 2B) and the intima/media ratio (0.08AE0.01 versus 0.16AE0.02; P<0.001) ( Figure 2C ).
Proliferation of SMCs and Inflammatory Cells After Cuff Injury
We evaluated the effect of AGP on cell proliferation at 7 days after injury by staining for a-smooth muscle cell actin, proliferating cell nuclear antigen, and lymphocyte antigen 6 complex. The a-smooth muscle cell actin-positive areas in the neointima were significantly decreased in mice treated with AGP (percent a-smooth muscle cell actin area within external elastic lumina: 30.8AE3.1 versus 45.4AE6.0%, P<0.001) ( Figure 3A and 3B). The percent proliferating cell nuclear antigen-positive nuclei were significantly decreased in the neointima of mice treated with AGP compared with saline (1.5AE0.2 versus 11.5AE0.8%; P<0.001) (Figure 4 ). The lymphocyte antigen 6 complex-positive areas in the neointima were significantly decreased in mice treated with AGP compared with saline (4.3AE0.5 versus 10.9AE2.8%; P=0.012) ( Figure 5 ). Figure 6 shows the expression of the proinflammatory cytokine TNF-a and MCP-1 after cuff injury determined using immunohistochemistry and real-time PCR. Figure 6B 
Expression of Inflammatory Cytokine
Evaluation of NF-jB Activation
To examine postinjury NF-jB activation in the arteries of both AGP and control groups, we performed pNF-jB staining in the injured arteries of both groups at 7 days postinjury. 
Discussion
This is the first investigation into how AGP affects injured arteries in vivo. AGP significantly reduced inflammation, SMC proliferation, and the TNF-a and MCP-1 levels in the injured arteries of LKO mice. Levels of fasting blood sugar and serum cholesterol did not significantly differ between AGP and control groups of LKO mice. These results suggest that AGP reduced neointimal formation by suppressing inflammation and smooth muscle proliferation independently of lipid and glycemic profiles. Recent studies have identified anti-atherosclerogenic effects of AGP in noninjured aortic arteries from low-density lipoprotein receptor-deficient and apolipoprotein E-deficient mice. 1,3 AGP also decreased mRNA levels of the inflammatory cytokines (TNF-a, IL-6, and IL-1b) in mononuclear cells and attenuated monocyte migration activity that was stimulated by TNF-a. These findings support our results. Although we also evaluated plasma levels of IL-6 and TNF-a in each group using an ELISA kit (Invitrogen) at 7 days postinjury, the results showed that the plasma levels of TNF-a and IL-6 were not significantly different between AGP-treated mice and salinetreated mice (IL-6: 17.4AE7.5 versus 24.8AE7.7 pg/mL; P=0.52, TNF-a: 4.4AE0.7 versus 3.9AE0.7 pg/mL; P=0.46 [n=4 to 5 per group]), suggesting that the cuff injury could induce local inflammation around the vascular, but not systemic inflammation. Thus, we believe the cuff-injury model cannot be used for the evaluation of the effect of AGP on the suppression of systemic inflammation. Other models are needed for evaluation of the systemic anti-inflammatory effect of AGP. TNF-a activates NF-jB, which regulates macrophage migration and chemokine expression as well as SMC proliferation and migration. [11] [12] [13] [14] We previously showed that a TNFa receptor 1 antagonist attenuated intimal hyperplasia, indicating that TNF-a signaling plays a critical role in the development of intimal hyperplasia after injury. 15 Here, AGP suppressed TNF-a expression, which subsequently attenuated neointimal formation in the injured artery. Our previous report showed that NF-jB activation and translocation are increased in the response to cuff injury. 15 Furthermore, our preliminary study revealed that an inhibitor of IkBa phosphorylation (BAY11-7082, Wako) prevented intimal hyperplasia completely in injured arteries of both AGP-treated and saline-treated mice (data not shown), suggesting that NF-jB activation is a major contributor to neointimal hyperplasia in cuff-injured arteries. Then, we performed pNF-jB staining in the injured arteries of both groups at 7 days postinjury. The results revealed that AGP treatment reduced NF-jB activation in the intima, media, and adventitia of injured arteries significantly compared with saline treatment. Taken together, AGP suppresses inflammation and neointimal hyperplasia in the cuff-injured artery by partially inhibiting NF-jB activation.
Recent reports have described the anti-atherogenic effects of DPP-4 inhibitors. Lim et al showed that sitagliptin suppressed neointimal formation after carotid artery balloon injury in rats. 16 Matsubara et al and Ervinna et al reported that both sitagliptin and anagliptin exerted anti-atherogenic effects in ApoE-deficient mice fed with a standard diet. trations of GLP-1. 18, 19 A recent study has found that exendin-4 (GLP-1 receptor agonist) modulated monocyte adhesion to endothelial cells and attenuated atherosclerosis in mice and that these effects might contribute to the inhibition of p65 nuclear translocation in macrophages by means of cAMP levels that are increased by GLP-1 receptor activation. 20 Another study found that exendin-4 suppresses SMC proliferation in arteries after wire injury. 21 Furthermore, Matsubara et al showed that DPP-4 inhibitors and GLP-1 produce anti-inflammatory effects that are followed by increases in cytosolic cAMP levels and decreases in extracellular signal-regulated kinase (ERK) 1/2 and c-jun N-terminal kinase (JNK) phosphorylation as well as NF-jB activation in vitro. 17 The cAMP/Protein kinase A (PKA) pathway attenuates TNF-a production in macrophages, 22 and the present study found that AGP suppresses TNF-a expression in the injured artery. These findings suggest that GLP-1 levels increased by AGP significantly contribute to the anti-inflammatory effects of AGP though activating cAMP/PKA signaling. However, it is not clear whether the anti-inflammatory effects of DPP-4 inhibitors depend on GLP-1. Levels of active GLP-1 after AGP administration in the present study were much lower than those of the GLP-1 analog (exendin-4) that exerted antiatherosclerogenic effect in another study 21 (GLP-1 in our study: 5 to 7 pmol/L to GLP-1 analogue: 10 nmol/L), suggesting that DPP-4 may directly suppress atherosclerosis. SMC proliferation participates in both the early and late phase of arterial diseases. 23 NF-jB is a common regulator of proinflammatory genes. SMC proliferation and CARD11 mediate factor-specific activation of NF-jB. 24 Interaction between DPP-4 and CARD11 leads to NF-jB activation in Tcells. 25 Such activation was reduced by DPP-4 or CARD11 knockdown, and SMCs proliferation was dose-dependently attenuated by sitagliptin via suppressing NF-jB activation in vitro. 16 In the present study, we show that AGP also attenuated SMC proliferation by suppressing NF-jB activation in vivo. The ERK pathway is also an important signaling cascade in inflammation. 26 An in vitro study found that AGP reduced SMCs proliferation and attenuated ERK phosphorylation in SMCs, and that AGP reduces TNF-a production and NF-jB activation in monocytes. 2 These findings suggest that inflammation and SMC proliferation might be suppressed by DPP-4 inhibitors directly, and not via GLP-1-dependent pathways. DPP-4 inhibitors exert cardiovascular protective effects via other pathways. Several reports showed that AGP improved endothelial function through a GLP-1 independent pathway that includes NO release via the Src-Akt-eNOS pathway. 27, 28 Levels of stromal-derived factor-1a (SDF-1a), which is another physiological substrates of DPP-4, are increased by DPP-4 inhibitors and this might affect endothelial progenitor cells that mediate cardiovascular repair. 29, 30 Levels of fasting blood sugar levels and serum cholesterol did not significantly differ between AGP-and salinetreated LKO mice. These findings are consistent with those of a study showing that AGP administration for 12 weeks did not change blood pressure or the lipid and glycemic profiles in LKO mice with a diet containing normal amounts of fat.
1 Clinical data also suggest that AGP exerts minor effects on lipid profiles. 4, 6 In conclusion, AGP suppressed intimal hyperplasia caused by vascular inflammation such as atherosclerosis and helped to reduce the frequency of cardiovascular events. 
